

.....

Growth Hormone Deficiency in Adults

.....

Frontiers of Hormone Research

Vol. 33

Series Editor

Ashley B. Grossman London

KARGER

.....

Growth Hormone Deficiency in Adults

Volume Editors

Jens Otto Lunde Jørgensen Aarhus

Jens Sandahl Christiansen Aarhus

14 figures and 13 tables, 2005



KARGER

Basel · Freiburg · Paris · London · New York ·
Bangalore · Bangkok · Singapore · Tokyo · Sydney

.....

Jens Otto Lunde Jørgensen, MD

Medical Department M
Aarhus University Hospital
Aarhus, Denmark

Jens Sandahl Christiansen, MD

Medical Department M
Aarhus University Hospital
Aarhus, Denmark

Library of Congress Cataloging-in-Publication Data

Growth hormone deficiency in adults / volume editors, Jens Otto Lunde Jørgensen, Jens Sandahl Christiansen.

p. ; cm. – (Frontiers of hormone research, ISSN 0301-3073; v. 33)

Includes bibliographical references and index.

ISBN 3–8055–7992–6 (hard cover : alk. paper)

1. Dwarfism, Pituitary. 2. Somatotropin–Therapeutic use. 3. Growth disorders.

[DNLN:1. Human Growth Hormone–deficiency–Adult. 2. Human Growth Hormone–therapeutic use–Adult. 3. Hormone Replacement Therapy–Adult. 4. Hypopituitarism–complications–Adult. 5.

Hypopituitarism–etiology–Adult. 6. Hypopituitarism–therapy–Adult. WK 550 G88398 2005] I. Jørgensen, Jens O. L. II. Christiansen, Jens Sandahl.

III. Series.

RC658.7.G77 2005

616.4'7–dc22

2005018888

Bibliographic Indices. This publication is listed in bibliographic services.

Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 2005 by S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland)

www.karger.com

Printed in Switzerland on acid-free paper by Reinhardt Druck, Basel

ISSN 0301–3073

ISBN 3–8055–7992–6

.....

Contents

VII Foreword

Grossman, A.B. (London)

IX Preface

Jørgensen, J.O.L.; Christiansen, J.S. (Aarhus)

1 Clinical Aspects of Growth Hormone Deficiency in Adults. An Overview
Jørgensen, J.O.L.; Christiansen, J.S. (Aarhus)

21 Epidemiology of Adult Growth Hormone Deficiency. Prevalence, Incidence,
Mortality and Morbidity
Erfurth, E.M. (Lund)

33 Hypopituitarism following Traumatic Brain Injury
Popovic, V. (Belgrade); Aimaretti, G. (Turin);
Casanueva, F.F. (Santiago de Compostela); Ghigo, E. (Turin)

45 IGF-I Measurements. Epidemiological and Clinical Aspects
Juil, A. (Copenhagen)

68 Diagnosis of Growth Hormone Deficiency
Fisker, S. (Aarhus); Andersen, M. (Odense); Ørskov, H. (Aarhus)

86 Clinical Monitoring of Growth Hormone Replacement in Adults
Gibney, J. (Dublin); Johannsson, G. (Gothenburg)

- 103 Consequences of Growth Hormone Deficiency for Intermediary Metabolism and Effects of Replacement**
Nørrelund, H. (Aarhus)
- 121 Skeletal and Cardiac Muscle in Adults with Growth Hormone Deficiency**
Cuneo, R.C.; Wallace, J.D. (Brisbane)
- 146 Bone Metabolism and Growth Hormone Deficiency.** Experimental and Clinical Aspects
Ueland, T.; Bollerslev, J. (Oslo)
- 161 Growth Hormone and Fluid Homeostasis**
Møller, J. (Aarhus)
- 185 Growth Hormone and Body Composition**
Mersebach, H.; Feldt-Rasmussen, U. (Copenhagen)
- 196 Effects of Growth Hormone Deficiency and Growth Hormone Treatment on Quality of Life in Growth Hormone-Deficient Adults**
Arwert, L.I.; Deijen, J.B.; Drent, M.L. (Amsterdam)
- 209 Safety Aspects of Growth Hormone Replacement**
Waterhouse, M.; Monson, J.P. (London)
- 222 Author Index**
- 223 Subject Index**

.....

Foreword

Just over 20 years ago, I published a paper into the effects of radiotherapy on pituitary tumors, and noted that the only major endocrinopathy that occurred early was growth hormone deficiency: I dismissed this finding as ‘this was of no clinical relevance since the patients were adult’ [Br Med J 1984;288: 110–1109]. How things have changed since then. Not only is the syndrome of adult-onset growth hormone deficiency (AGHD) now well recognized and described in detail, but thousands of adult patients throughout the world are being treated with synthetic growth hormone on a regular basis. Much of the early work on describing the syndrome originated in Europe, and the editors of this volume have been at the forefront in this area from its inception. It now seems appropriate at this point to draw breath, and assess exactly what is the current status of AGHD, what are its defining clinical and biochemical features, what are the risks and benefits of treatment, and what progress is likely in the future. The editors of this volume have brought together a superb group of international experts in this area, and I am sure that this will become an essential sourcebook for all practicing endocrinologists who take care of patients with adult-onset growth hormone deficiency.

Ashley B. Grossman, London

.....

Preface

Growth hormone (GH) is essential for longitudinal growth and it has been known for more than 40 years that GH-deficient children benefit from replacement with the hormone. Based on experimental studies and Nature's own experiment with acromegaly it is, however, an even older observation that GH has important biological actions in adults. In 1989, it was demonstrated that GH deficiency in hypopituitary adults was associated with distinct abnormalities, which could be reversed by GH replacement, and since 1994 this treatment modality has been a licensed indication in most countries. Controversies do, however, remain within this field and novel data continue to emerge.

This book provides an update on some of the pending issues. It encompasses the traditional end points of GH therapy such as body composition, bone biology and physical performance. Attention is also devoted to diagnostic aspects and side effects. Additional features range from clinical epidemiology to quality of life, and novel areas such as the impact of traumatic brain injury on pituitary function are also covered. The contributions stem from recognized clinicians and scientists, who have been working in the field for decades.

Jens Otto Lunde Jørgensen, Aarhus
Jens Sandahl Christiansen, Aarhus

